AE37: A novel T-cell-eliciting vaccine for breast cancer

Alan K. Sears; Sonia A. Perez; Guy T. Clifton; Linda C. Benavides; Jeremy D. Gates; Kevin S. Clive; Jarrod P. Holmes; Nathan M. Shumway; David C. Van Echo; Mark G. Carmichael; Sathibalan Ponniah; Constantin N. Baxevanis; Elizabeth A. Mittendorf; Michael Papamichail; George E. Peoples

doi:10.1517/14712598.2011.616889

AE37: A novel T-cell-eliciting vaccine for breast cancer

Alan K. Sears, Sonia A. Perez, Guy T. Clifton, Linda C. Benavides, Jeremy D. Gates, Kevin S. Clive, Jarrod P. Holmes, Nathan M. Shumway, David C. Van Echo, Mark G. Carmichael, Sathibalan Ponniah, Constantin N. Baxevanis, Elizabeth A. Mittendorf, Michael Papamichail, George E. Peoples

Surgical Oncology

Research output: Contribution to journal › Article › peer-review

42 Scopus citations

Abstract

Introduction: Immunotherapy, including vaccines targeting the human EGFR2 (HER-2/neu) protein, is an active area of investigation in combatting breast cancer. Several vaccines are currently undergoing clinical trials, most of which are CD8 ⁺ T-cell-eliciting vaccines. AE37 is a promising primarily CD4 ⁺ T-cell-eliciting HER-2/neu breast cancer vaccine currently in clinical trials. Areas covered: This article reviews preclinical investigations as well as findings from completed and ongoing Phase I and Phase II clinical trials of the AE37 vaccine. Expert opinion: Clinical trials have shown the AE37 vaccine to be safe and capable of generating peptide-specific, durable immune responses. This has been shown in patients with any level of HER-2/neu expression. Early clinical findings suggest there may be benefit to AE37 vaccination in preventing breast cancer recurrence.

Original language	English (US)
Pages (from-to)	1543-1550
Number of pages	8
Journal	Expert Opinion on Biological Therapy
Volume	11
Issue number	11
DOIs	https://doi.org/10.1517/14712598.2011.616889
State	Published - Nov 2011

Keywords

AE36 peptide
AE37 vaccine
Breast cancer
Cancer vaccines
Ii-Key hybrid
Prostate cancer

ASJC Scopus subject areas

Pharmacology
Drug Discovery
Clinical Biochemistry

Access to Document

10.1517/14712598.2011.616889

Cite this

Sears, A. K., Perez, S. A., Clifton, G. T., Benavides, L. C., Gates, J. D., Clive, K. S., Holmes, J. P., Shumway, N. M., Van Echo, D. C., Carmichael, M. G., Ponniah, S., Baxevanis, C. N., Mittendorf, E. A., Papamichail, M., & Peoples, G. E. (2011). AE37: A novel T-cell-eliciting vaccine for breast cancer. Expert Opinion on Biological Therapy, 11(11), 1543-1550. https://doi.org/10.1517/14712598.2011.616889

Sears, AK, Perez, SA, Clifton, GT, Benavides, LC, Gates, JD, Clive, KS, Holmes, JP, Shumway, NM, Van Echo, DC, Carmichael, MG, Ponniah, S, Baxevanis, CN, Mittendorf, EA, Papamichail, M & Peoples, GE 2011, 'AE37: A novel T-cell-eliciting vaccine for breast cancer', Expert Opinion on Biological Therapy, vol. 11, no. 11, pp. 1543-1550. https://doi.org/10.1517/14712598.2011.616889

@article{05ecf1641aff4e4cadeb05c5b22bfc2d,

title = "AE37: A novel T-cell-eliciting vaccine for breast cancer",

abstract = "Introduction: Immunotherapy, including vaccines targeting the human EGFR2 (HER-2/neu) protein, is an active area of investigation in combatting breast cancer. Several vaccines are currently undergoing clinical trials, most of which are CD8 + T-cell-eliciting vaccines. AE37 is a promising primarily CD4 + T-cell-eliciting HER-2/neu breast cancer vaccine currently in clinical trials. Areas covered: This article reviews preclinical investigations as well as findings from completed and ongoing Phase I and Phase II clinical trials of the AE37 vaccine. Expert opinion: Clinical trials have shown the AE37 vaccine to be safe and capable of generating peptide-specific, durable immune responses. This has been shown in patients with any level of HER-2/neu expression. Early clinical findings suggest there may be benefit to AE37 vaccination in preventing breast cancer recurrence.",

keywords = "AE36 peptide, AE37 vaccine, Breast cancer, Cancer vaccines, Ii-Key hybrid, Prostate cancer",

author = "Sears, {Alan K.} and Perez, {Sonia A.} and Clifton, {Guy T.} and Benavides, {Linda C.} and Gates, {Jeremy D.} and Clive, {Kevin S.} and Holmes, {Jarrod P.} and Shumway, {Nathan M.} and {Van Echo}, {David C.} and Carmichael, {Mark G.} and Sathibalan Ponniah and Baxevanis, {Constantin N.} and Mittendorf, {Elizabeth A.} and Michael Papamichail and Peoples, {George E.}",

year = "2011",

month = nov,

doi = "10.1517/14712598.2011.616889",

language = "English (US)",

volume = "11",

pages = "1543--1550",

journal = "Expert Opinion on Biological Therapy",

issn = "1471-2598",

publisher = "Informa Healthcare",

number = "11",

}

TY - JOUR

T1 - AE37

T2 - A novel T-cell-eliciting vaccine for breast cancer

AU - Sears, Alan K.

AU - Perez, Sonia A.

AU - Clifton, Guy T.

AU - Benavides, Linda C.

AU - Gates, Jeremy D.

AU - Clive, Kevin S.

AU - Holmes, Jarrod P.

AU - Shumway, Nathan M.

AU - Van Echo, David C.

AU - Carmichael, Mark G.

AU - Ponniah, Sathibalan

AU - Baxevanis, Constantin N.

AU - Mittendorf, Elizabeth A.

AU - Papamichail, Michael

AU - Peoples, George E.

PY - 2011/11

Y1 - 2011/11

N2 - Introduction: Immunotherapy, including vaccines targeting the human EGFR2 (HER-2/neu) protein, is an active area of investigation in combatting breast cancer. Several vaccines are currently undergoing clinical trials, most of which are CD8 + T-cell-eliciting vaccines. AE37 is a promising primarily CD4 + T-cell-eliciting HER-2/neu breast cancer vaccine currently in clinical trials. Areas covered: This article reviews preclinical investigations as well as findings from completed and ongoing Phase I and Phase II clinical trials of the AE37 vaccine. Expert opinion: Clinical trials have shown the AE37 vaccine to be safe and capable of generating peptide-specific, durable immune responses. This has been shown in patients with any level of HER-2/neu expression. Early clinical findings suggest there may be benefit to AE37 vaccination in preventing breast cancer recurrence.

AB - Introduction: Immunotherapy, including vaccines targeting the human EGFR2 (HER-2/neu) protein, is an active area of investigation in combatting breast cancer. Several vaccines are currently undergoing clinical trials, most of which are CD8 + T-cell-eliciting vaccines. AE37 is a promising primarily CD4 + T-cell-eliciting HER-2/neu breast cancer vaccine currently in clinical trials. Areas covered: This article reviews preclinical investigations as well as findings from completed and ongoing Phase I and Phase II clinical trials of the AE37 vaccine. Expert opinion: Clinical trials have shown the AE37 vaccine to be safe and capable of generating peptide-specific, durable immune responses. This has been shown in patients with any level of HER-2/neu expression. Early clinical findings suggest there may be benefit to AE37 vaccination in preventing breast cancer recurrence.

KW - AE36 peptide

KW - AE37 vaccine

KW - Breast cancer

KW - Cancer vaccines

KW - Ii-Key hybrid

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=80053643169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053643169&partnerID=8YFLogxK

U2 - 10.1517/14712598.2011.616889

DO - 10.1517/14712598.2011.616889

M3 - Article

C2 - 21895539

AN - SCOPUS:80053643169

SN - 1471-2598

VL - 11

SP - 1543

EP - 1550

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

IS - 11

ER -

AE37: A novel T-cell-eliciting vaccine for breast cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this